Items where authors include "Hatswell, A.J."

Export as [feed] Atom [feed] RSS
Number of items: 17.

Article

Pennington, B. orcid.org/0000-0002-1002-022X, Eaton, J., Hatswell, A.J. et al. (1 more author) (2022) Carers’ health-related quality of life in global health technology assessment: guidance, case studies and recommendations. PharmacoEconomics, 40 (9). pp. 837-850. ISSN 1170-7690

Hatswell, A.J., Bullement, A. orcid.org/0000-0001-7091-0972, Schlichting, M. et al. (1 more author) (2021) What is the impact of the analysis method used for health state utility values on QALYs in oncology? A simulation study comparing progression-based and time-to-death approaches. Applied Health Economics and Health Policy, 19 (3). pp. 389-401. ISSN 1175-5652

Bullement, A. orcid.org/0000-0001-7091-0972, Podkonjak, T., Robinson, M.J. et al. (4 more authors) (2020) Real-world evidence use in assessments of cancer drugs by NICE. International Journal of Technology Assessment in Health Care, 36 (4). pp. 388-394. ISSN 0266-4623

Bullement, A. orcid.org/0000-0001-7091-0972, Willis, A., Amin, A. et al. (3 more authors) (2020) Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. BMC Medical Research Methodology, 20. 103. ISSN 1471-2288

Bullement, A. orcid.org/0000-0001-7091-0972, McMordie, S.T., Hatswell, A.J. et al. (2 more authors) (2020) Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia A in Italy incorporating real-world dosing and joint health data. PharmacoEconomics - Open, 4. pp. 133-142. ISSN 2509-4262

Bullement, A. orcid.org/0000-0001-7091-0972, Taylor, M., McMordie, S.T. et al. (2 more authors) (2019) NICE, in confidence : an assessment of redaction to obscure confidential information in single technology appraisals by the National Institute for Health and Care Excellence. PharmacoEconomics, 37 (11). pp. 1383-1390. ISSN 1170-7690

Di Tanna, G.L., Porter, J.K., Lipton, R.B. et al. (5 more authors) (2019) Migraine day frequency in migraine prevention: longitudinal modelling approaches. BMC Medical Research Methodology, 19. 20. ISSN 1471-2288

Hatswell, A.J., Bullement, A., Briggs, A. et al. (2 more authors) (2018) Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models. Pharmacoeconomics, 36 (12). pp. 1421-1426. ISSN 1170-7690

Lipton, R.B., Brennan, A. orcid.org/0000-0002-1025-312X, Palmer, S. et al. (7 more authors) (2018) Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. Journal of Medical Economics (JME), 21 (7). pp. 666-675. ISSN 1369-6998

Bullement, A. orcid.org/0000-0001-7091-0972, Underhill, S., Fougeray, R. et al. (1 more author) (2018) Cost-effectiveness of trifluridine/tipiracil for previously treated metastatic colorectal cancer in England and Wales. Clinical Colorectal Cancer, 17 (1). e143-e151. ISSN 1533-0028

Hatswell, A.J., Porter, J., Lee, D. et al. (2 more authors) (2016) The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight. Value in Health, 19 (8). pp. 1055-1058. ISSN 1098-3015

Hatswell, A.J., Pennington, B., Pericleous, L. et al. (3 more authors) (2014) Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health and Quality of Life Outcomes, 12. 140. ISSN 1477-7525

Proceedings Paper

Li, N., Bullement, A. orcid.org/0000-0001-7091-0972, McMordie, S. et al. (2 more authors) (2019) RO4 Cost-effectiveness analysis of rFVIIIFc, PEGylated rFVIII, and emicizumab for the prophylactic treatment of severe hemophilia A patients without inhibitors in the United States. In: Value in Health. ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, 18-22 May 2019, New Orleans, LA, USA. Elsevier , S389.

Hatswell, A.J., Bullement, A. orcid.org/0000-0001-7091-0972, Schlichting, M. et al. (1 more author) (2019) PCN259 Should health state utility values (HSUVS) in cancer immunotherapies (IOS) be analyzed by time to death (TTD) or progression status? Results of a simulation study. In: Value in Health. ISPOR 2019 : Rapid. Disruptive. Innovative: A New Era in HEOR, 18-22 May 2019, New Orleans, LA, USA. Elsevier BV , S105-S105.

Bullement, A. orcid.org/0000-0001-7091-0972, Amin, A., Stapelkamp, C. et al. (5 more authors) (2018) Modelling overall survival in immunotherapy using parametric techniques : Avelumab in previously treated metastatic Merkel cell carcinoma. In: Value in Health. ISPOR 21st Annual European Meeting, 10-14 Nov 2018, Barcelona, Spain. Elsevier , S11-S11.

Bullement, A. orcid.org/0000-0001-7091-0972 and Hatswell, A.J. (2018) MO2 - How errors in the implementation of background mortality leads to bias in models. In: Value in Health. ISPOR 8th Asia-Pacific Conference, 08-11 Sep 2018, Tokyo, Japan. Elsevier , S8.

Hatswell, A.J., Cooper, M., Bharmal, M. et al. (1 more author) (2017) Predicting outcomes from multiple uncontrolled historical studies of standard care – progression-free survival and overall survival in untreated metastatic Merkel cell carcinoma. In: Value in Health. ISPOR 20th Annual European Congress, 04-08 Nov 2017, Glasgow, Scotland. Elsevier , A422.

This list was generated on Sat Mar 23 20:57:47 2024 GMT.